Milestones

Dates retain their source precision. Elapsed windows await verification; they never become completed events automatically. Completed shows selected milestones already recorded in the evidence during the past 90 days, not a complete event archive or evidence of approval or clinical benefit. These status labels follow today’s date without advancing a research check.

Milestones

Scheduled events24

TOGETHER-PsA one-year ACR presentation

TOGETHER-PsA week 52 ACR oral presentation

Oveporexton Schedule IV rule publication and effectiveness

STEP Young full pediatric BMI and safety results at ObesityWeek.

Aleniglipron ACCESS extension and dose-ranging posters at ObesityWeek, 2:30–3:30 p.m. Eastern

Trontinemab Brainshuttle CTAD symposium, 4:50–5:30 p.m. ET

Enobosarm QUALITY post-hoc aged ≥65 physical-function report

Detailed RADIANT remlifanserin Alzheimer-psychosis findings after the Phase 2 primary-endpoint miss.

RG6434 Phase 1 safety and neuroinflammation symposium, 2:35–3:15 p.m. ET

PrevenTRON trial design at CTAD, 9:55–10:05 a.m. ET

BHV-1530 Phase 1 update in Barcelona at 10:00 as stated by the sponsor; full combination-cohort efficacy and safety remain to be assessed.

Ibogaine early-trial RFI comments close; not an efficacy readout.

SLS009 relapsed/refractory AML Phase 2 ASH poster

Hetlioz jet-lag administrative hearing

Giredestrant advanced ESR1-mutated breast-cancer application; target is not guaranteed approval.

VOCERYQ confirmatory draft protocol due

Otarmeni confirmatory protocol due; this is not a clinical readout.

mFlusiva postmarketing safety-study protocol due; not a public efficacy readout.

ICER COMP360 draft evidence report scheduled.

ICER COMP360 New England CEPAC public meeting scheduled; evidence/value discussion, not FDA approval.

VOCERYQ confirmatory final protocol due

HER2CLIMB-05 interim OS report submission

VOCERYQ confirmatory study completion due

VOCERYQ confirmatory final report due

2026 forecast windows108

Initial generic lenacapavir country supplies

VDPHL01 Study 302 Part B twelve-month extension/safety results.

Separate Phase 2 PP405 study in women expected to initiate; actual start not verified.

Separate frontline SLS009 early topline

REGAL preliminary overall-survival topline

ELUMINA efficacy and harms readout

VK3019 single-ascending-dose completion

APPROACH Phase 3 efficacy and safety results

ASC39 Phase 1 initiation

LY4247147 estimated start

ACTIVATE-HFpEF estimated start

GP0112 cheek trial estimated start

ARTISTRY-3 estimated start

Female PP405 AWAKENING start

Simenafil Alzheimer estimated start

LY4086940 Phase 2 start

EDIT-401 estimated trial start

Expected U.S. ORZEYFUL launch only after DEA scheduling and required labeling supplement

AMPLIFY-2 estimated start; not yet recruiting in October 20 snapshot

SUNRISE-1 and SUNRISE-2 estimated starts; supersedes October 15/16 plans, no first dosing verified

SUPRA-COPD urolithin A estimated start.

SOARA ovarian blood-screening safety/diagnostic-burden study estimated start.

NCT07853716 start; no public-result date inferred.

Postoperative suzetrigine NCT07856654 study start.

CagriSema hypertension estimated start

HNK experimental-pain estimated start

Rejuran S neck study estimated start

Crisaborole/excimer vitiligo primary completion

3D-BOT randomized trial start

Kylo-0603 MASLD Phase 2a estimated start

TEV-53408 Phase 2b/3 vitiligo program estimated start

Clarity AD initial five-year extension presentation, 6 p.m. Eastern

Pancoronavirus Phase 1 estimated start

CHF5993 adolescent asthma Phase 3 start.

CELIA late-breaking symposium, 4:45–5:25 p.m. Eastern

LEADER three-year real-world session, 11–11:40 a.m. Eastern

Olatorepatide Phase 3 estimated start

YKYY032 estimated Phase 2 start

Ixazomib HIV-reservoir study estimated start; ART continues.

UBT48128 estimated start

LungScreen-NEMO start

BGM1812 estimated start

MOTIVATION maternal GBS estimated start

AI biliary CT estimated primary completion

Crisaborole/excimer vitiligo final completion

LEAP2 estimated study start

Recombinant zoster vaccine cardiovascular-outcomes estimated start.

TARGET-CHD estimated start

Facial-vitiligo topical comparison primary completion

SmartEnLite estimated start

CCC hypoglossal stimulation estimated start

Belotero Intense U.S. commercial availability; approval was earlier.

NCT07850752 start; no public-result date inferred.